Balyasny Asset Management
TXG icon

Balyasny Asset Management’s 10x Genomics TXG Stock Holding History

Balyasny Asset Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-65,000
Closed -$3.63M – 2809
2023
Q1 		$3.63M Buy
+65,000
New +$3.04M 0.01% 1205

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Balyasny Asset Management's TXG Position: Q2 2026 in Review

Balyasny Asset Management sold out of 10x Genomics (TXG) in Q2 2026, closing a stake of 989,522 shares — an estimated $21M sold.

Balyasny Asset Management first reported a position in TXG in Q2 2020 and held it in 10 quarters. The position peaked at $37.8M in Q1 2023. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Balyasny Asset Management reported no remaining 10x Genomics position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 989,522 10x Genomics shares in Q2 2026, an estimated $21M.
  • Balyasny Asset Management first reported a position in 10x Genomics in Q2 2020 and held it in 10 quarters.
  • Balyasny Asset Management's 10x Genomics position peaked at $37.8M in Q1 2023.
  • 393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.